Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinica ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System ...

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

HUTCHMED will host a webcast to discuss the data presented at the ASCO Annual Meeting at 8:30 -9:00 am HKT on Tuesday, June 3, 2025 (8:30 - 9:00 pm EDT on June 2, 2025). The event will be held in ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...